Embed Size (px)
Citation preview
Maximizing Emerging Technology’s Potential
Chris L. Waller, Ph.D.October 2011
1
Outline
• Industry Drivers for Change– Vertical Disintegration and Selective Sourcing
• The Pistoia Alliance– A Pre-competitive Technology Development Experiment
• eHealth– A Transformative Opportunity for Pharma Driven by Emerging
Technologies
• Pharma 2.0– The Emerging Research Alliance Network Model and The
Importance of Technology Partners
R&D: Long, Expensive, and Risky
1614121086420
Years
Cost = $1.3B/new drug
TargetSelection
ChemicalSelection
ClinicalTrials
Launch
Discovery(2-10 years)
Pre-clinical TestingLaboratory and animal testing
Phase 120-80 healthy volunteers - safety and dosage
Phase 2100-300 patient volunteers efficacy & safety
Phase 33,000-5,000 patient volunteers used to monitor
adverse reactions to long-term use
FDA Review/Approval
Productivity is Decreasing
4
Source: Tufts Center for the Study of Drug development, PhRMA
Industry Driver: Externalization
DA
TA
CR
OB
IO C
RO
CH
EM
CR
OP
HA
RM
A
REGISTER
DESIGN
ASSAY
REPORT
DISTRIBUTE
SYNTHESIZE
PHARMA
CHEM
BIO
DATA
PH
AR
MA
DISTRIBUTEREGISTER ASSAYSYNTHESIZE REPORTDESIGN
SelectivelyIntegrated
Model
Fully Internal Model
Cost pressures, disruptive technologies, and other forces often drive business processes to be externalized.
Pharma
Biotech
Academia
Opportunities
6
Co-PIs, Institutions
Partnerships, JBVs
Alliances, Acquisitions
Pharma
Biotech
Academia
Opportunities
7
Tech. Transfer, Start-ups
Tech. Transfer, Acquisitions
Pistoia Alliance:Description and Purpose
MissionTo streamline pre-competitive workflow elements of pharmaceutical research and development by specifying common business terms, relationships and processesGoal • Develop taxonomies and vocabularies,
application interface specifications, data dictionaries, data models, etc.
• Establish standards that will be embraced by producers and consumers of pre-competitive workflows
Pistoia Alliance: Membershipas of: August 26, 2009
>65 Individuals from 18 member organizations
10
Technology Trends Supporting eHealth
Now 20122011 2020+2015
DTC Genetic Testing
Dx-Rx Kits
RFID
Low Power SenorsNanofibers
GPS
Grid Computing
SOA
Microfuidics
Biomarker
PHR
EHR
Unified CommunicationsSelf MonitoringHealth devicesTelehealth
Remote Monitoring
Personal WellnessPlans
PreImplantationGenetic Diagnosis
Personal Genome Record
Microarrays
OpenSource (Hadoop, Crossbow)
Senor Nets(atom+, Zigbee, Blue Lite)
IPv6, IPSec
VOIP
Mobile BroadcastwiMax
Mobile IP
Biometric Senors
BioPhotonics
Molecular Imaging
Optical Diagnostics
DNA Sequencing
RxAuthentication
4G, LTE
Internet of Thingsc
Ambient Networking
Holographic Storagec
Digital Paper
SaaS
PaaS
IaaS
Health Xchanges
Health OutcomesRegistries
Behavior Sensors
Ultra WideBand
Semantic Web
Personal Agents
Device Convergence
Mobile Payments
Quantum Cryptography
Nano Photonics
Predictive Models
Social MiningUtility Computing
3D UISocial Networks
Real-time analytics
Rapid Diagnostic Kits
BioMedical Modeling
Solution/Service/Product Technologies
Webservices
Portals
EMR
Digital Workflow
XMPP
Cloud computing
Personal Assist Devices
Telemedicine
Smartphones
Communities
Search
Smart Apps
Imaging sensors
Digitization of Health Information
Digitizationof HealthCommunication
Decreasing Costs of Sensors
Decreasing Cost of DNA Sequencing
IncreasedComputational AnalyticsCapabilities
eHealth Focused Portfolio
11
Clinical Data Flow and Uses
Uses of Clinical Data for R&D
Adverse Event Reporting Utility
Health Economics Analytics
Patient-centric Provider-centric
Health & Wellness Consumer Electronics
Health & Wellness Self-Management Services
Care provision augmentation
Clinical Decision Support Aids
1a
1b
2a
2b
3a
3b
3c
New Product and Services
eHealth Strategic Priority Areas for 2010 need to be developed and validated in concert with the BUs, RUs, Divisions, and the Leadership Team
Business Innovation within Pharma
BusinessDiversification beyond Pharma
Well Being / Nokia / iPhone
PACeR
Maccabi
Keas
DAER/ASTER
Evolving paradigm for the discovery of medicines (Collaborative) A vision that points towards open innovation and collaborations Open research model to collectively share scientific expertise
Enhance speed of drug discovery beyond individual resource capabilities (Speed) Limited research budgets and capabilities driving greater shared resources Goal to see all partners succeed by accelerating the SCIENCE
Synergize Pfizer’s strengths with Research Partners (Knowledge) Pair Pfizer’s design, cutting edge tools, synthetic excellence with research partners (academics, not-for-
profits, venture capitalists, or biotechs) to develop break through science, novel targets, and indications of unmet medical need
Current example of academic and not-for-profits partners (Discover and Publish) Drive to publish in top journal with science receiving high visibility and interest
Body clock mouse study suggests new drug potentialMon, Aug 23 2010By Kate Kelland
LONDON (Reuters) - Scientists have used experimental drugs being developed by Pfizer to reset and restart the body clock of mice in a lab and say their work may offer clues on a range of human disorders, from jetlag to bipolar disorder.
Contacts: Travis Wager ([email protected]) Paul Galatsis ([email protected])
a few months ago we entered into a collaboration with the giant pharmaceutical industry Pfizer to test some of
their leading molecules for potential relevance to HD.
The Evolving Pfizer R&D Ecosystem
Horizon 2 Horizon 3Horizon 1
Emerging Technology Watch List
Collaboration and Interconnectivity
Integration Services
Disruptive Business Innovation
Digital Platforms
Mobility
Enterprise Federated Infrastructure
